Livermore Lab wins $3.5M anthrax vaccine grant with Loyola University

Lawrence Livermore National Laboratory and Loyola University won a $3.5 million grant from the National Institutes of Health to develop a new anthrax vaccine.
This is the first grant from the NIH that focuses on a particular type of vaccine using nanolipoprotein, or NLP, technology developed at the lab.

Lawrence Livermore to work with Keiretsu Forum angel investors

Lawrence Livermore National Laboratory will sign a memorandum of understanding with the Keiretsu Forum, a group of angel investors.
The deal, to be presented Thursday by Erik Stenehjem of the lab’s industrial partnerships office and Randy Williams of the Keiretsu Forum, is to help with the commercialization of technology created at the lab.

CPAC adds jobs, shrinks proton therapy technology

Shrinking the size and cost of a giant cancer-fighting machine could help a young Livermore company supplant X-rays as it adds 25 new East Bay jobs by year end.
Compact Particle Acceleration Corp., a spinoff of publicly traded Tomo Therapy Inc. of Madison, Wis., used a partnership with Lawrence Livermore National Laboratory to build a device that delivers electrically charged protons directly into a cancer tumor to damage the cells’ DNA.

Livermore Lab kills antibiotic-resistant bacteria with their own genes